A small-molecule c-Rel inhibitor reduces alloactivation of T cells without compromising antitumor activity

Cancer Discovery

Volumn 4, Issue 5, 2014, Pages 578-591

  Shono, Yusuke ^a   Tuckett, Andrea Z ^a   Ouk, Samedy ^b   Liou, Hsiou Chi ^b   Altan Bonnet, Grégoire ^a   Tsai, Jennifer J ^a   Oyler, Jennifer E ^a   Smith, Odette M ^a   West, Mallory L ^a   Singer, Natalie V ^a   Doubrovina, Ekaterina ^a   Pankov, Dmitry ^a   Undhad, Chandresh V ^a   Murphy, George F ^c   Lezcano, Cecilia ^c   Liu, Chen ^d   O'Reilly, Richard J ^a   van den Brink, Marcel R M ^a   Zakrzewski, Johannes L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; IT 603; LPAM 1 PROTEIN; OCTAMER TRANSCRIPTION FACTOR 1; PEPTIDES AND PROTEINS; PROTEIN INHIBITOR; STAT5 PROTEIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR REL; UNCLASSIFIED DRUG; [(5Z) 5 [(5 BROMO 2 HYDROXY 3 METHOXYPHENYL)METHYLIDENE] 2 SULFANYLIDENEIMIDAZOLIDIN 4 ONE; LYMPHOCYTE ANTIGEN RECEPTOR; MOLECULAR LIBRARY;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL ALLOACTIVATION; CELLULAR PARAMETERS; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DNA BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GEL MOBILITY SHIFT ASSAY; GRAFT VERSUS HOST REACTION; HIGH THROUGHPUT SCREENING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE; TANDEM MASS SPECTROMETRY; ADVERSE EFFECTS; ALLOTRANSPLANTATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; C57BL MOUSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; GRAFT VERSUS TUMOR EFFECT; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MOLECULAR LIBRARY; MOUSE; PHARMACOLOGY;

ANIMALS; FEMALE; GENE EXPRESSION REGULATION; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PROTO-ONCOGENE PROTEINS C-REL; RECEPTORS, ANTIGEN, T-CELL; SMALL MOLECULE LIBRARIES; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84899699955     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-13-0585     Document Type: Article

References (48)

1. Appelbaum FR. The current status of hematopoietic cell transplantation. Annu Rev Med 2003; 54: 491-512.
2. Jenq RR, van den Brink MR. Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nat Rev Cancer 2010; 10: 213-21.
3. Ferrara JL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transplant 1999; 5: 347-56.
4. Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 2011; 29: 2230-9.
5. Bouchlaka MN, Redelman D, Murphy WJ. Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effects. Immunotherapy 2010; 2: 399-418.
6. Fowler DH. Shared biology of GVHD and GVT effects: potential methods of separation. Crit Rev Oncol Hematol 2006; 57: 225-44.
7. Liou HC, Jin Z, Tumang J, Andjelic S, Smith KA, Liou ML. c-Rel is crucial for lymphocyte proliferation but dispensable for T cell effector function. Int Immunol 1999; 11: 361-71.
8. Visekruna A, Volkov A, Steinhoff U. A key role for NF-kappaB transcription factor c-Rel in T-lymphocyte-differentiation and effector functions. Clin Dev Immunol 2012; 2012: 239368.
9. Fullard N, Wilson CL, Oakley F. Roles of c-Rel signalling in inflammation and disease. Int J Biochem Cell Biol 2012; 44: 851-60.
10. Yu Y, Wang D, Kaosaard K, Liu C, Fu J, Haarberg K, et al. c-Rel is an essential transcription factor for the development of acute graftversus-host disease in mice. Eur J Immunol 2013; 43: 2327-37.
11. Liou HC, Hsia CY. Distinctions between c-Rel and other NF-kappaB proteins in immunity and disease. Bioessays 2003; 25: 767-80.
12. Reinhard K, Huber M, Wostl C, Hellhund A, Toboldt A, Abass E, et al. c-Rel promotes type 1 and type 17 immune responses during Leishmania major infection. Eur J Immunol 2011; 41: 1388-98.
13. Hilliard BA. Critical roles of c-Rel in autoimmune inflammation and helper T cell differentiation. J Clin Invest 2002; 110: 843-50.
14. + CD4 regulatory T cells. PLoS ONE 2011; 6: e26851.
15. Guckel E, Frey S, Zaiss MM, Schett G, Ghosh S, Voll RE. Cell-intrinsic NF-kappaB activation is critical for the development of natural regulatory T cells in mice. PLoS ONE 2011; 6: e20003.
16. Vang KB, Yang J, Pagan AJ, Li LX, Wang J, Green JM, et al. Cutting edge: CD28 and c-Rel-dependent pathways initiate regulatory T cell development. J Immunol 2010; 184: 4074-7.
17. Ruan Q, Kameswaran V, Tone Y, Li L, Liou HC, Greene MI, et al. Development of Foxp3(D) regulatory t cells is driven by the c-Rel enhanceosome. Immunity 2009; 31: 932-40.
18. Ruan Q, Chen YH. Nuclear factor-kappaB in immunity and inflammation: the Treg and Th17 connection. Adv Exp Med Biol 2012; 946: 207-21.
19. Ruan Q, Kameswaran V, Zhang Y, Zheng S, Sun J, Wang J, et al. The Th17 immune response is controlled by the Rel-RORgamma-RORgamma T transcriptional axis. J Exp Med 2011; 208: 2321-33.
20. Ouk S, Liou ML, Liou HC. Direct Rel/NFkB inhibitors: structural basis for mechanism of action. Future Med Chem 2009; 1: 1683-707.
21. Liou HC, Tian W, Cheng S, Hsia CY, Owyang A, Hsu JJ, inventors; Cornell Research Foundation, Inc., assignee. Methods and compositions for targeting c-Rel. United States Patent EP 2010225. 2009 Jan 7.
22. Doan LL, Tanner MK, Grimes HL. Intranuclear staining of proteins in heterogeneous cell populations and verification of nuclear localization by flow cytometric analysis. J Immunol Methods 2003; 279: 193-8.
23. Hofer T, Krichevsky O, Altan-Bonnet G. Competition for IL-2 between regulatory and effector T cells to chisel immune responses. Front Immunol 2012; 3: 268.
24. Feinerman O, Jentsch G, Tkach KE, Coward JW, Hathorn MM, Sneddon MW, et al. Single-cell quantification of IL-2 response by effector and regulatory T cells reveals critical plasticity in immune response. Mol Syst Biol 2010; 6: 437.
25. Weiss JM, Bilate AM, Gobert M, Ding Y, Curotto de Lafaille MA, Parkhurst CN, et al. Neuropilin 1 is expressed on thymus-derived natural regulatory T cells, but not mucosa-generated induced Foxp3n T reg cells. J Exp Med 2012; 209: 1723-42.
26. Yadav M, Louvet C, Davini D, Gardner JM, Martinez-Llordella M, Bailey-Bucktrout S, et al. Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med 2012; 209: 1713-22.
27. Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol 2007; 8: 191-7.
28. Deenick EK, Elford AR, Pellegrini M, Hall H, Mak TW, Ohashi PS. c-Rel but not NF-kappaB1 is important for T regulatory cell development. Eur J Immunol 2010; 40: 677-81.
29. + CD4 regulatory T cells. J Exp Med 2009; 206: 3001-14.
30. Trivedi D, Williams RY, O'Reilly RJ, Koehne G. Generation of CMVspecific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy. Blood 2005; 105: 2793-801.
31. Yang H, Thomas D, Boffa DJ, Ding R, Li B, Muthukumar T, et al. Enforced c-REL deficiency prolongs survival of islet allografts1. Transplantation 2002; 74: 291-8.
32. Finn PW, He H, Ma C, Mueller T, Stone JR, Liou HC, et al. Molecular profiling of the role of the NF-kappaB family of transcription factors during alloimmunity. J Leukoc Biol 2002; 72: 1054-62.
33. Levin AM, Bates DL, Ring AM, Krieg C, Lin JT, Su L, et al. Exploiting a natural conformational switch to engineer an interleukin-2 "superkine. Nature 2012; 484: 529-33.
34. + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003; 9: 1144-50.
35. + regulatory T cells inhibit GVHD and preserve general immunity in humanized mice. Sci Transl Med 2013; 5: 168ra9.
36. Doubrovina E, Oflaz-Sozmen B, Prockop SE, Kernan NA, Abramson S, Teruya-Feldstein J, et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBVuulymphomas after allogeneic hematopoietic cell transplantation. Blood 2012; 119: 2644-56.
37. Sun K, Welniak LA, Panoskaltsis-Mortari A, O'Shaughnessy MJ, Liu H, Barao I, et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci U S A 2004; 101: 8120-5.
38. Vodanovic-Jankovic S, Hari P, Jacobs P, Komorowski R, Drobyski WR. NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145. Blood 2006; 107: 827-34.
39. Egan LJ. I B-kinase-dependent NF-B activation provides radioprotection to the intestinal epithelium. Proc Natl Acad Sci U S A 2004; 101: 2452-7.
40. Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999; 18: 6938-47.
41. + T cells. J Exp Med 2003; 198: 569-80.
42. Hanash AM, Dudakov JA, Hua G, O'Connor MH, Young LF, Singer NV, et al. Interleukin-22 protects intestinal stem cells from immunemediated tissue damage and regulates sensitivity to graft versus host disease. Immunity 2012; 37: 339-50.
43. Liou HC, Sha WC, Scott ML, Baltimore D. Sequential induction of NF-kappa B/Rel family proteins during B-cell terminal differentiation. Mol Cell Biol 1994; 14: 5349-59.
44. Cooke KR, Kobzik L, Martin TR, Brewer J, Delmonte J, Crawford JM, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood 1996; 88: 3230-9.
45. Petrovic A, Alpdogan O, Willis LM, Eng JM, Greenberg AS, Kappel BJ, et al. LPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versushost disease. Blood 2004; 103: 1542-7.
46. Zakrzewski JL, Kochman AA, Lu SX, Terwey TH, Kim TD, Hubbard VM, et al. Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation. Nat Med 2006; 12: 1039-47.
47. Clarke JL, Pao W, Wu N, Miller VA, Lassman AB. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 2010; 99: 283-6.
48. Qin W, Tao H, Chen Y, Chen Z, Wu N. Sensitive, accurate and simple liquid chromatography-tandem mass spectrometric method for the quantitation of amphotericin B in human or minipig plasma. J Chromatogr Sci 2012; 50: 636-43.